Genetic Selection in Startups: Just Good Science, Not Eugenics

In the ever-evolving landscape of biotechnology, one startup has caused quite a stir by offering parents the ability to select embryos based on their genetic makeup. Noor Siddiqui, a former Thiel fellow and the brains behind Orchid, aims to revolutionize reproductive technology by allowing parents to choose which embryos to incubate based on their genetic composition. While some may view this practice as a form of eugenics, Siddiqui vehemently argues that it is all in the name of reducing suffering.

In a recent interview with Wired, Siddiqui passionately defended her startup, emphasizing that the goal of Orchid is to prevent genetic diseases and ultimately decrease human suffering. The founder’s vision is to give parents the power to select embryos with the best genetic traits, such as those free from debilitating illnesses. Despite the controversial nature of her work, Siddiqui remains resolute in her belief that Orchid is a force for good in the world.

The conversation took an unexpected turn when the interviewer raised the sensitive topic of eugenics, a term that Siddiqui seemed uncomfortable associating with her company. Refusing to acknowledge the parallels between genetic selection and eugenics, Siddiqui maintained that her intentions were rooted in compassion and a desire to prevent unnecessary suffering. However, critics argue that the concept of choosing embryos based on their genetic traits inherently raises ethical concerns.

Orchid sets itself apart from competitors by offering a comprehensive genetic screening process that analyzes the entire genome of embryos. This thorough approach comes with a hefty price tag of $2,500 per embryo screened, attracting a select clientele willing to invest in the future health of their offspring. Despite its innovative technology, Orchid’s practices have sparked a debate about the ethical implications of genetic selection in reproductive medicine.

As the interview delved into contentious topics such as population decline and the legacy of scandal-ridden companies like Theranos, Siddiqui’s resilience in defending Orchid’s mission became apparent. While her commitment to using biotechnology for the betterment of humanity is commendable, the blurred lines between genetic selection and eugenics remain a point of contention. The emergence of services like Orchid serves as a stark reminder of the ethical dilemmas posed by advancements in reproductive technology and the complex moral questions they raise.